RADNOR, Pa.--(BUSINESS WIRE)--PolyMedix, Inc. (OTCBB: PYMX), an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has initiated a Phase 2 clinical trial in Canada with its novel defensin-mimetic antibiotic, PMX-30063. PMX-30063 represents a new class of antibiotics, and is the first and only systemic antibiotic specifically designed to mimic the activity of human host defense proteins, the body’s natural defense against bacterial infections.
